Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects
Department of Dermatology, St.-Lukes Roosevelt Hospital Center, New York
Noah Scheinfeld MD
DOJ 9 (3): 6
Phenytoin (diphenylhydantoin or Dilantin) is a highly effective and widely prescribed anticonvulsant agent used in the treatment of grand mal and psychomotor epilepsy. In dermatology, phenytoin has been used to treat ulcers, epidermolysis bullosa, and inflammatory conditions. Its mechanism appears to involve its ability to inhibit collagenase. Its topical use for the promotion of wound healing seems promising but requires further trials. The side effects of phenytoin continue to create significant morbidity. Common side effects include gingival hyperplasia, coarsening of the facies, and hirsutism. Rarer cutaneous side effects include drug-induced lupus, purple-hand syndrome, pigmentary alterations, and IgA bullous dermatosis. It can cause generalized cutaneous eruptions that include a maculopapular exanthem, Stevens-Johnson syndrome, generalized exfoliative dermatitis, toxic epidermal necrolysis, vasculitis, and fixed-drug eruptions. Phenytoin is linked to a hypersensitivity syndrome manifested by fever, rash, and lymphadenopathy. Patients receiving phenytoin may develop pseudolymphoma or, rarely, malignant lymphoma and mycosis-fungoides-like lesions. Phenytoin can effect clotting function. Phenytoin can alter vitamin and mineral levels. Prenatal exposure to phenytoin may result in a spectrum of structural, developmental, and behavioral changes known as the fetal hydantoin syndrome. After 60 years of use, phenytoin uses and mechanisms of action have yet to be fully defined; the drug remains a useful tool and an important subject for additional research.
In 1938, Merritt and Putnam published their noteworthy data using phenytoin to treat major, absence, and psychic equivalent seizures. Since that time, phenytoin (diphenylhydantoin or Dilantin) (Fig. 1) has been demonstrated to be a highly effective anticonvulsant. Even decades later, it continues to be a widely prescribed anticonvulsant and antiarrhythmic agent in the treatment of grand mal and psychomotor epilepsy. It is part of the hydantoin family that includes mephenytoin (Mesantoin), phenylethylhydantoin (Nirvanol), and fosphenytoin.
|Structure of phenytoin|
Phenytoin has been investigated as a treatment for more than 100 diseases. A Medline search in November of 2002 showed that 12,860 articles concerning it have been published since 1966. In dermatology, phenytoin has been investigated to treat ulcers, epidermolysis bullosa, and inflammatory conditions. Numerous allergic, and proliferative, idiosyncratic cutaneous side effects have been reported with its use. This review summarizes its uses, mechanisms, and cutaneous side effects.
Scientific basis and treatment of epidermolysis bullosa
Researchers have investigated the effects of phenytoin on a cellular level. In some patients with epidermolysis bullosa, levels of collagenase are increased. Phenytoin inhibits collagenase in-vitro. By inhibiting collagenase activity, phenytoin has been theorized to stabilize collagen fibrils and thus decrease blister formation. Phenytoin reduces the contraction of recessive dystrophic epidermolysis bullosa fibroblast populated collagen gels. Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblast cultures. When fibroblasts are embedded within freely contracting, relaxed, type I collagen matrices, they are insensitive to phenytoin. However, if fibroblasts are grown in collagen matrices that are nonretracting and under tension, phenytoin stimulates cell proliferation and inhibits collagenase activity. Patients with epidermolysis bullosa treated with phenytion had lower levels of inflammatory mediators such as arachidonic acid in plasma and erythrocyte phospholipids than did untreated epidermolysis bullosa patients.
Some studies have shown that phenytoin is useful in treating recessive dystrophic epidermolysis bullosa and in reducing its blister count.[9, 10] Such efficacy has been noted in case reports of single patients in Taiwan and Italy. It has been used in short- and long-term management of dystrophic epidermolysis bullosa. Phenytoin has been an adjunct in the management of esophageal stenosis in epidermolysis bullosa. The aforementioned studies not withstanding, however, a large study conducted by the Epidermolysis Bullosa Study Group did not find phenytoin effective in treating dystrophic epidermolysis bullosa.
Phenytoin appears more effective in the treatment of other epidermolysis bullosa variants. It has been used to treat junctional epidermolysis bullosa.[16, 17] In one case, it reduced blister formation by 50 percent after two months of treatment (2 mg/kg increased to 15 mg/kg/day with a serum level of 12-15 µg/ml). The disease flared 1 week after discontinuance. Another study found it effective in treating two patients with generalized atrophic benign EB (GABEB) and ineffective in treating two patients with Herlitz disease. Others have found it ineffective for treating junctional epidermolysis bullosa. It has been used to treat the Dowling-Meara variant of epidermolysis bullosa simplex. Topical phenytoin (2 %-5 % cream twice daily) has been found helpful in treating the ulcers of epidermolysis bullosa simplex.
Phenytoin has been studied (mostly with inadequate controls) in the healing of pressure ulcers, venous stasis ulcers, diabetic ulcers, traumatic wounds, and burns. Used topically, it appears to enhance healing without side effects. Its wound-related pharmacology has been investigated. Phenytoin increases gene expression of the platelet-derived growth factor B chain in macrophages and monocytes. Healthy granulation tissue appears earlier with phenytoin than with conventional saline dressings. Phenytoin may promote wound healing through multiple mechanisms, including stimulation of fibroblast proliferation, facilitation of collagen deposition, glucocorticoid antagonism, and antibacterial activity.
Phenytoin seems promising in enhancing the healing of decubitus ulcers. In a comparison involving 47 patients with stage II decubitus ulcers, treatment with phenytoin, DuoDerm® dressings or triple antibiotic ointment applications all resulted in reduction of the ulcers. However, the phenytoin group demonstrated more rapid results in all aspects of ulcer healing. Similarly, one study suggests that phenytoin may be superior to honey as a topical agent in the treatment of chronic ulcers.
Phenytoin has been used to treat ulcers that result from mycobacterial infections. It has been used orally and topically to treat the trophic ulcers of leprosy.[31, 32, 33] In such a role, it is more effective than saline. It can be used in the treatment of the Buruli ulcer of Mycobacterium ulcerans.
Topical phenytoin was used with good effect during the Iran-Iraq war when other resources were limited. In Iran, it was reported to have a role in treating 19 wounds caused by missiles and 6 refractory ulcers in civilians. In Iraq, it was reported that topical phenytoin in the treatment of war-related decubitus ulcers resulted in prompt pain relief, decreased wound exudate and bacterial contamination, in enhanced granulation-tissue formation, and in more rapid healing. Such results might make phenytoin a useful agent in countries with limited access to more expensive wound-care therapies.
Other inflammatory and genetic conditions
Phenytoin has been used to treat a variety of collagen vascular diseases, genetic, and inflammatory conditions. It has been used to treat linear scleroderma (en coup de sabre morphea) in children with good effect in the 1970s  and 1990s. It has been used in the treatment of discoid lupus erythematosus, but its effect was not confirmed in an evidence-based analysis. It can be used to treat the painful tonic-dystonic spasms in Sjögren syndrome. Phenytoin might have a role in treating pachyonychia congenita. It increases insulin sensitivity and might ameliorate acanthosis nigricans. Orally and topically, it has been used to treat lichen planus and oral lichen planus. It has been used with good effect to treat rheumatoid arthritis but appears to be less effective than gold salts. Its benefits can be sustained, and the usual dose is 300 mg/day for this condition. Phenytoin is not widely used for any of the aforementioned conditions.
Phenytoin has been used to treat neuropathic pain. It now appears, however, that gabapentin is preferred to treat such pain over other anticonvulsants. Carbamazepine and phenytoin were the first anticonvulsants to be used in controlled clinical trials and shown to relieve painful diabetic neuropathy and paroxysmal attacks in trigeminal neuralgia. However, an evidence-based review of these trials found them unproven in affect. Similarly, phenytoin was found ineffective in the treatment of diabetic symmetrical polyneuropathy.
Immune function and phenytoin
Phenytoin has complex effects on the immune system. Phenytoin suppresses cytotoxic activities of cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTL), but not lymphokine-activated killer (LAK) cells. Phenytoin treatment preferentially induces a Th2-type response. Phenytoin also significantly depresses interferon augmentation of NK cell cytotoxicity in a dose-dependent manner. Phenytoin suppresses the production of cortisol. Specifically, phenytoin induces the liver cytochrome P450 enzyme system and stimulates steroid clearance. It can also induce adrenal suppression. These effects may partially explain the side effects of phenytoin, which are forms of immune dysfunction.
Common side effects
There are a few common cutaneous side effects of phenytoin. About 50 percent of patients on long-term phenytoin therapy develop gingival hyperplasia. Long-term phenytoin can lead to a coarsening of the facies, enlargement of the lips, and thickening of the scalp and face. These changes occur in one-third of institutionalized patients on long-term therapy. Coarse facies develop in one phenytoin-treated sister of each of two pairs of identical twins.
Phenytoin can also cause hirsutism. It occurs in about 12 percent of children receiving phenytoin, usually within 3 months of initiating therapy. It occurs on the extensor surfaces of the extremities and on the trunk and face. It usually resolves within 1 year of discontinuing therapy but sometimes does not.
A variety of side effects have been noted in epileptics who have taken phenytoin or other convulsants both together or consecutively. A South African study compared cutaneous conditions occurring in 173 epileptics aged 6-19 compared with 211 age-matched controls. Anticonvulsants used singly or in combination were carbamazepine in 54.9 percent, phenytoin in 47.8 percent, barbiturates in 36.6 percent and ethosuximide in 11.2 percent. The most frequent combination was phenytoin and carbamazepine—14 percent of males and 18.4 percent of females. Hirsutism was found in 43.9 percent of the female epileptics compared to 7.5 percent of controls. Punctate and linear scars on the dorsum of the hands of 27.7 percent epileptics compared to 3.8 percent nonepileptics. Both ephilides and nevocellular nevi occurred in 12.7 percent of the epileptics compared to 29.4 percent and 52.1 percent, respectively, of controls. Leukonychia was found in 52 percent of epileptics and 28.9 percent of nonepileptics. Acne incidence was 80.3 percent in epileptic compared to 30.2 percent in nonepileptic females. These results were roughly replicated in a Brazilian study. These results differ from a study that found no significant increase in the prevalence of acne nor the sebum excretion rate in 243 patients taking phenytoin or other convulsants compared with 2,167 unmedicated controls.
Collagen-vascular-like side effects
A number of reports have linked phenytoin to drug-induced lupus and collagen vascular disease. It has caused subacute lupus, dermatomyositis, systemic lupus with vasculitis, systemic lupus with arthritic manifestations, and alopecia linked with lupus. Lupus can occur in children taking phenytoin. One report has linked phenytoin to the development of a systemic sclerosis like disease, and one patient developed scleroderma while taking it. Phenytoin-induced pseudo-Sjögren syndrome that included infiltrated salivary glands has been noted.
Vitamin, minerals, and phenytoin
Phenytoin use can alter vitamin levels. Pellagrous dermatitis has been induced by phenytoin in children. This effect has been noted in combination with other medications in a mentally handicapped patient who promptly responded to vitamin therapy. Phenytoin can affect biotin metabolism. This effect has been marked with long-term therapy and has been speculated to be one cause of the eruptions induced by phenytoin and a subject of basic research. Phenytoin can decrease folic acid levels.
Phenytoin has a variety of effects on copper, zinc, and magnesium in the hair, skin, and serum of epileptics. In one study, the levels of serum copper, zinc, copper-zinc superoxide dismutase, and malondialdehyde were significantly increased, but the glutathione level was significantly decreased, in epileptic patients using phenytoin monotherapy compared with those of the controls. Others, too, have reported increases in serum copper levels. Some have reported zinc deficiency in users of phenytoin, and others have reported that zinc levels in controls and users are the same. The clinical effects of these alterations are unclear.
The effects of phenytoin on calcium are complex. In a study of institutionalized patients, those who took it had lower serum calcium than those who did not. In an American study, epilepsy, and its therapy, including the newer drugs, are risk factors for low bone density, irrespective of vitamin D levels. Skeletal monitoring with the institution of appropriate therapy is indicated in patients on chronic antiepileptic therapy. However, these effects were not replicated in a Brazilian study.
Phenytoins effects on blood chemistry are complex as well. High-density lipoprotein cholesterol (HDL-C) was significantly higher in the epileptic children than in two control groups: healthy non-epileptic children and epileptic children before starting anticonvulsant therapy.
Generalized cutaneous eruptions
The reported incidence of cutaneous eruptions with phenytoin use varies. Cutaneous reactions in patients with head injuries receiving phenytoin for seizure prophylaxis are seen in 19.4 percent. Another review estimated that 5-10 percent of patients have cutaneous reactions who take phenytoin; specifically, 5 percent of children have transient maculopapular exanthems often within 3 weeks of drug initiation; a higher percentage have these reactions if a high loading dose is given. Still another review stated 2-3 percent of patients taking phenytoin develop exanthems.
Phenytoin can induce a variety of generalized eruptions and systemic complications that include maculopapular eruptions, Stevens-Johnson syndrome, generalized exfoliative dermatitis, toxic epidermal necrolysis, vasculitis, follicular or pustular eruptions, erythema multiforme, angioedema, and fixed-drug eruptions. To understand the relative frequency of these eruptions, researchers reviewed the records of 42 hospitalized patients with phenytoin reactions. The cutaneous manifestations reported were maculopapular eruptions (71.4 %), Stevens-Johnson syndrome (14.3 %), fever (4 %), generalized exfoliative dermatitis (2.4 %), toxic epidermal necrolysis (2.4 %), vasculitis (2.4 %) and agranulocytosis (2.4 %). In a large study, 4 percent of fixed-drug eruptions were caused by phenytoin, many of which were generalized. Allergy to phenytoin can be assessed with patch testing in 60 percent of cases.
Some of the eruptions that phenytoin causes occur only in combination with other medications or treatments. This concept is suggested by a report of a man who developed acne-keloidalis-like lesions in the scalp during treatment with phenytoin and carbamazepine. Combined intake of phenytoin, corticosteroids, and H2-blockers has resulted in cases of toxic epidermal necrolysis, exanthematous eruption and hypersensitivity syndrome. The combination of radiation therapy, and pheyntoin appears to increase the incidence of Stevens-Johnson syndrome.
Phenytoin causes a hypersensitivity syndrome that manifests with fever, rash, and lymphadenopathy. Its incidence is one in 1,000-10,000 exposures. It is also seen with other aromatic antiepileptic drugs: carbamazepine, phenobarbital, and primidone, with frequent cross-sensitivity. Hypersensitivity syndrome usually occurs 2-8 weeks after initiation of therapy. In one case, hypersensitivity syndrome stimulated the reactivation of human herpesvirus 6. A report notes reactivation of cytomegalovirus.
Often its initial sign is fever with malaise and pharyngitis, sometimes with a strawberry tongue. An eruption follows and ranges from a macularpapular exanthem to toxic epidermal necrolysis. This eruption can manifest as erythroderma or can mimic the exanthem of staphylococcal toxic shock syndrome or infectious mononucleosis. It can manifest with a generalized pustular eruption, which can be follicular based. The liver is often involved. The kidney, central nervous system, or lungs may be involved in hypersensitivity syndrome. Hypothyroidism may occur about 2 months after initial symptom outbreak. Hypersensitivity syndrome usually manifests with elevated liver enzymes and eosinophilia. There can be a hepatitis that can manifest with jaundice.
Immediate discontinuation of phenytoin is the sine qua non of effective treatment of the hypersensitivity syndrome that it induces. Valproic acid can usually be substituted with minimal concern for cross-reactivity but should be used cautiously in the face of hepatitis. Gabapentin and lamotrigine do not generally induce hypersensitivity syndrome in those who suffer from phenytoin-induced hypersensitivity syndrome. Patients with phenytoin-induced hypersensitivity syndrome can somtimes be managed supportively with hydration, antihistamines, H2-receptor blockers, and topical corticosteroids. In the face of significant internal systemic reaction, systemic corticosteroids, starting at 1 mg/kg/day, should be used for at least 1 month. Tapering is often difficult without precipitating a flare. The use of intravenous immune globulin should be limited to severe cases in which Kawasaki disease or idiopathic thrombocytopenic purpura remain diagnostic concerns.
The etiology of hypersensitivity syndrome is complex. The aromatic anticonvulsants are metabolized to hydroxylated aromatic compounds, such as arene oxides. If detoxification of this toxic metabolite is insufficient, the toxic metabolite may bind to cellular macromolecules causing cell necrosis or a secondary immunological response. Anticonvulsant hypersensitivity syndrome has been linked to a defect in the enzyme epoxide hydrolase. It has been suggested that the incidence of this defect is highest in elderly black males. It appears to be familial.
Intravenous phenytoin (used most often to treat status epilepticus) can cause purple-hand syndrome. It is characterized by edema, discoloration, and pain distal to the site of intravenous administration. In one study of patients taking phenytoin, it occurred in 3 of 179 patients. In another study it occurred in 9 of 152 patients treated with phenytoin. Subacute local cutaneous reactions in patients receiving intravenous phenytoin occurred in 29 of 115 consecutive patients studied (25.2 %; 22 mild and 7 moderate); all resolved within 3 weeks. Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin has been reported.
Fosphenytoin is a water-soluble disodium phosphate ester of phenytoin that is converted in plasma to phenytoin. Fosphenytoin is compatible with most common intravenous solutions and can be administered safely through the intramuscular route. An additional safety factor is the absence of propylene glycol in the fosphenytoin formulation. Propylene glycol is used as a vehicle in the intravenous phenytoin preparation and by itself may produce serious cardiovascular complications. Fosphenytoin administration resulted in significantly less venous irritation and phlebitis compared with an equimolar dose of phenytoin. It causes more pruritus than phenytoin. In one study, it induced pruritus in 49 percent of cases. Further study of this ester of phenytoin will be needed to determine if it is a safer intravenous preparation to use in the long run.
Phenytoin can affect pigmentation. It can induce chloasma and melasma. Acquired acromelanosis has been caused by phenytoin. Universal cutaneous depigmentation following phenytoin-induced toxic epidermal necrolysis has been noted.
Phenytoin can induce porphyria. In one patient, phenytoin increased skin pigmentation and hirsutism, decreased serum IgA level, and apparently unmasked hereditary coproporphyria. It can also unmask acute intermittent porphyria.  Acute intermittent porphyria has occurred in patients on phentoin therapy with normal erythrocyte porphobilinogen deaminase activity. Phenytoin also can affect the development of porphyria cutanea tarda. It has also led to the development of unclassified porphyria. It can be part of the multifactorial development of porphyria.
Phenytoin rarely induces other types of inflammatory and disorders of keratinization. Phenytoin has been linked to drug-induced linear IgA bullous dermatosis. It may be linked to the development of sarcoidosis, specifically pulmonary sarcoidosis. Thickening of the heel pad associated with long-term phenytoin therapy has been reported.
Patients receiving phenytoin may develop benign lymphoid hyperplasia, pseudolymphoma, pseudo-pseudolymphoma, or, rarely, malignant lymphoma. Lymphoid hyperplasia can be localized in the cervical area. Enlargement of inguinal lymph nodes during chronic phenytoin therapy has been reported.
Pseudolymphoma has manifested with generalized nodular lesions. Obtaining a history of phenytoin use is crucial in the diagnosis of such patients. Southern blots, gene-rearrangement studies and chromosome studies are important tools in differentiating pseudolymphoma from malignant lymphoma in patients receiving chronic therapy.
Phenytoin-induced pseudolymphoma can have mycosis fungoides manifestations, sometimes with lymphocyte dysregulation. Mycosis-fungoides-like lesions associated with phenytoin and carbamazepine therapy have been noted elsewhere. Phenytoin resulted in a mycosis-fungoides-like eruption in cancer patient. Two localized erythematous plaques of mycosis fungoides were noted in a patient whose eruption resolved 3 weeks after phenytoin was discontinued. Other cases of mycosis-fungoides-like patches have been localized.
Lymphoma in several forms is associated with phenytoin. Cases have been reported of pseudolymphoma that resolved after phenytoin was discontinued only to recur as frank lymphoma. Other cases of malignant lymphoma have been associated with phenytoin. Phenytoin has been linked to Hodgkin disease as well. A history of prolonged phenytoin therapy was reported by 8 of 516 patients (1.6 %) with Hodgkin disease or non-Hodgkin lymphoma, as compared with 3 of 516 patients (0.6 %) with other cancers, and 2 of 516 (0.4 %) tumor-free individuals, showing a small increase of malignancy with phenytoin use. Another report found in phenytoin use in 2.3 percent of cancer patients compared to 0.6 percent of controls.
Phenytoin can effect clotting function and result in eruption. Dilantin-induced disseminated intravascular coagulation with purpura fulminans has occurred. A 12-year-old boy developed a clinical picture of high fever, scarlatiniform eruption, hemorrhagic (purpuric) skin lesions on his buttocks and neck, stomatitis, and conjunctivitis within 2 weeks after phenytoin administration, related to disseminated intravascular coagulation. Phenytoin has induced serum sickness with fibrin-platelet thrombi in lymph node microvasculature. It can also cause lupus anticoagulants and prothrombin deficiency, which can result in thrombotic eruptions. Some have suggested that vitamin K be given to mother taking phenytoin in third trimester to prevent hemorrhage. However, a policy of giving vitamin K throughout the last third of pregnancy to all women being treated with anticonvulsants, recently recommended, is not justified by the available evidence.
Prenatal exposure to phenytoin may result in a spectrum of structural, developmental, and behavioral changes known as the fetal hydantoin syndrome (FHS). Varied malformations caused by hydantoin (phenytoin) intake during pregnancy include digit and nail hypoplasia, growth retardation, typical facial appearance, rib anomalies, abnormal palmar creases, hirsutism, and low hairlines. Ambiguous genitalia are rarely associated with this syndrome. A patient with the dysmorphic characteristics of FHS has manifested with unusual hyperpigmentation of several fingernails. Another neonate manifested with gum hypertrophy, digitalization of the thumbs, hypoplasia of the distal phalanges and nails, epicanthal folds, pseudohypertelorism, epidermoid cyst, and geographic tongue. Onychopathy can be a monosymptomatic or mild form of this syndrome. This syndrome may be associated with neonatal acne.
One study noted an increase incidence of facial clefts among epileptic patients and their children with an uncertain relationship to therapy. Another study did not bear this relationship out. Environmental factors are important in the development of such clefts. In sum, epilepsy, and phenytoin use seem of minor importance in regard to cleft development.
Phenytoin increases the metabolism of ethinylestradiol and progestogens, necessitating oral contraceptive preparations containing at least 50 mcg of ethinylestradiol. It induces failure of levonorgestrel implants and mandates that medroxyprogesterone injections be given every 10 rather than 12 weeks.
After 60 years of use, phenytoin uses and mechanisms continue to be defined. The inhibition of collagenase by phenytoin gives it a real role in facilitating the healing of ulcers. As was the case with topical tacrolimus, optimizing the vehicle that contains the topical phenytoin might optimize its effects. Phenytoin also has complex effects on the immune system, in particular an induction of a Th2-type response, which might underlie its common induction of eruptions and immunologic effects. It can also be seen as an antagonist of cortisol and this might buttress its effects on wound healing and immune dysregulation. It probably is under used in hard-to-treat conditions that involve excessive or dysfunctional production of collagen, such as morphea and epidermolysis bullosa. As is true with most other medications, more randomized double-blind studies would enhance our understanding of therapeutic efficacy. Possible areas of research include structure manipulation to enhance desired therapeutic effects and minimize the adverse effects that continue to create significant morbidity and must be considered before therapy is instituted. Phenytoin and related drugs remain promising therapies and fertile fields for future investigation.
References1. Silverman AK, Fairley J, Wong RC. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol. 1988;18:721-41.
2. Kero M. Epidermolysis bullosa in Finland. Clinical features, morphology, and relation to collagen metabolism. Acta Derm Venereol Suppl (Stockh). 1984;110:1-51.
3. Eisenberg M, Stevens LH, Schofield PJ. Epidermolysis bullosa--new therapeutic approaches. Australas J Dermatol. 1978;19:1-8.
4. Bauer EA, Gedde-Dahl T Jr, Eisen AZ The role of human skin collagenase in epidermolysis bullosa. J Invest Dermatol. 1977;68:119-24.
5. Talas G, Adams TS, Eastwood M, Rubio G, Brown RA. Phenytoin reduces the contraction of recessive dystrophic epidermolysis bullosa fibroblast populated collagen gels. Int J Biochem Cell Biol. 1997;29:261-70.
6. Moy LS, Tan EM, Holness R, Uitto J. Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblast cultures. Arch Dermatol. 1985;121:79-83.
7. Genever PG, Cunliffe WJ, Wood EJ. Influence of the extracellular matrix on fibroblast responsiveness to phenytoin using in vitro wound healing models. Br J Dermatol. 1995 ;133:231-5.
8. Cunnane SC, Kent ET, McAdoo KR, Caldwell D, Lin AN, Carter DM. Abnormalities of plasma and erythrocyte essential fatty acid composition in epidermolysis bullosa: influence of treatment with diphenylhydantoin J Invest Dermatol. 1987;89:395-9.
9. Abahussein AA, al-Zayir AA, Mostafa WZ, Okoro AN. Epidermolysis bullosa in the eastern province of Saudi Arabia. Int J Dermatol. 1993;32:579-81.
10. Recessive dystrophic epidermolysis bullosa treated with phenytoin. Int J Dermatol. 1992;31:730-2.
11. Yen SL, Chao LH, Ho MM, Hwang KC. Epidermolysis bullosa: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1990;31:383-7.
12. Altomare GF, Polenghi M, Pigatto PD, Nazzaro V, Piattoni F. Dystrophic epidermolysis bullosa inversa. Dermatologica. 1990;181:145-8.
13. Cooper TW, Bauer EA. Therapeutic efficacy of phenytoin in recessive dystrophic epidermolysis. A comparison of short- and long-term treatment. Arch Dermatol. 1984 ;120:490-5.
14. Kern IB, Eisenberg M, Willis S. Management of oesophageal stenosis in epidermolysis bullosa dystrophica. Arch Dis Child. 1989;64:551-6.
15. Caldwell-Brown D, Stern RS, Lin AN, Carter DM. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group. N Engl J Med. 1992;327:163-7.
16. Armoni M, Schlesinger M, Vardy PA, Metzker A. Phenytoin and junctional epidermolysis bullosa. Arch Dermatol. 1985;121:168-9
17. Nawaz A, Matta H, Jacobsz A, Al-Salem A. Congenital pyloric atresia and junctional epidermolysis bullosa: a report of two cases. Pediatr Surg Int. 2000;16:206-8.
18. Rogers RB, Yancey KB, Allen BS, Guill MF.Phenytoin therapy for junctional epidermolysis bullosa. Arch Dermatol. 1983 ;119:925-6.
19. Fine JD, Johnson L. Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa. Arch Dermatol. 1988;124:1402-6.
20. Oakley CA, Wilson N, Ross JA, Barnetson RS.Junctional epidermolysis bullosa in two siblings: clinical observations, collagen studies and electron microscopy. Br J Dermatol. 1984;111:533-43.
21. Larregue M, Bressieux JM, Fusade T, Matard B, Crampon P, Salhi A. Epidermolysis bullosa herpetiformis of Dowling-Meara. Ann Dermatol Venereol. 1990;117:802-4.
22. Masgrau-Peya E, Lacour M, Salomon D. Topical phenytoin accelerates healing in epidermolysis bullosa simplex. Dermatology. 1995;190:254.
23. Muthukumarasamy MG, Sivakumar G, Manoharan G.Topical phenytoin in diabetic foot ulcers. Diabetes Care. 1991;14:909-11.
24. Talas G, Brown RA, McGrouther DA. Role of phenytoin in wound healing--a wound pharmacology perspective. Biochem Pharmacol. 1999;57:1085-94.
25. Dill RE, Miller EK, Weil T, Lesley S, Farmer GR, Iacopino AM. Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J Periodontol. 1993;64:169-73.
26. Pendse AK, Sharma A, Sodani A, Hada S. Topical phenytoin in wound healing. Int J Dermatol. 1993;32:214-7
27. Anstead GM, Hart LM, Sunahara JF, Liter ME. Phenytoin in wound healing. Ann Pharmacother. 1996;30:768-75.
28. Margolis DJ, Lewis VL. A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers. Dermatol Surg. 1995;21:145-8.
29. Rhodes RS, Heyneman CA, Culbertson VL, Wilson SE, Phatak HM. Topical phenytoin treatment of stage II decubitus ulcers in the elderly. Ann Pharmacother. 2001;35:675-81.
30. Oluwatosin OM, Olabanji JK, Oluwatosin OA, Tijani LA, Onyechi HU. A comparison of topical honey and phenytoin in the treatment of chronic leg ulcers. Afr J Med Med Sci. 2000;29:31-4.
31. Bogaert H, Saleta B, Sanchez E, Garcia B. Trophic leprosy ulcers: treatment with topical and systemic phenytoin. Int J Dermatol. 1990;29:156-7.
32. Malhotra YK, Amin SS. Role of topical phenytoin in trophic ulcers of leprosy in India. Int J Lepr Other Mycobact Dis. 1991;59:337-8.
33. Malhotra YK, Amin SS. Role of topical phenytoin in trophic ulcers of leprosy in India. Int J Lepr Other Mycobact Dis. 1991;59:337-8.
34. Bansal NK, Mukul.Comparison of topical phenytoin with normal saline in the treatment of chronic trophic ulcers in leprosy. Int J Dermatol. 1993;32:210-3.
35. Adjei O, Evans MR, Asiedu A. Phenytoin in the treatment of Buruli ulcer. Trans R Soc Trop Med Hyg. 1998;92:108-9
36. Modaghegh S, Salehian B, Tavassoli M, Djamshidi A, Rezai AS. Use of phenytoin in healing of war- and non-w ar wounds. A pilot study of 25 cases. Int J Dermatol. 1989;28:347-50.
37. el Zayat SG. Preliminary experience with topical phenytoin in wound healing in a war zone. Mil Med. 1989;154:178-80
38 Neldner KH. Treatment of localized linear scleroderma with phenytoin. Cutis. 1978;22:569-72.
39. Eubanks LE, McBurney EI, Galen W, Reed R. Linear scleroderma in children. Int J Dermatol. 1996;35:330-6.
40. Rodriguez-Castellanos MA, Barba Rubio J, Barba Gomez JF, Gonzalez Mendoza A. Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol. 1995;131:620-1.
41. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2001;:CD002954.
42. Jabbari B, Salardini A. Painful tonic/dystonic spasms in Sjögren syndrome. Mov Disord. 1999;14:860-4.
43. Blank H. Treatment of pachyonychia congenita with phenytoin. Br J Dermatol. 1982;106:123.
44. Minaker KL, Flier JS, Landsberg L, Young JB, Moxley RT, Kingston WJ, Meneilly GS, Rowe JW.Phenytoin-induced improvement in muscle cramping and insulin action in three patients with the syndrome of insulin resistance, acanthosis nigricans, and acral hypertrophy. Arch Neurol. 1989;46:981-5.
45. Bogaert H, Sanchez E. Lichen planus: treatment of thirty cases with systemic and topical phenytoin. Int J Dermatol. 1990;29:157-8.
46. Eisen D The therapy of oral lichen planus. Crit Rev Oral Biol Med. 19.93;4:141-58.
47 Grindulis KA, Nichol FE, Oldham R. Phenytoin in rheumatoid arthritis. Ann Rheum Dis. 1988;47:261.
48. Richards IM, Fraser SM, Hunter JA, Capell HA. Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis. Ann Rheum Dis. 1987;46 667-9.
49. Macfarlane DG, Clark B, Panayi GS. Pilot study of phenytoin in rheumatoid arthritis. Ann Rheum Dis. 1986;45:954-6.
50. Grindulis KA, Nichol FE, Oldham R. Phenytoin in rheumatoid arthritis.J Rheumatol. 1986;13:1035-9.
51. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6 Suppl A:61-8.
52. Wiffen P, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000;:CD001133.
53. Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther. 1977;22:196-9.
54. Okamoto Y, Shimizu K, Tamura K, Yamada M, Matsui Y, Hayakawa T, Mogami H. ffects of anticonvulsants on cellular immunity. To Shinkei. 1989;41:299-304.
55. Okada K, Sugiura T, Kuroda E, Tsuji S, Yamashita U. Phenytoin promotes Th2 type immune response in mice. Clin Exp Immunol. 2001;124:406-13.
56. Margaretten NC, Hincks JR, Warren RP, Coulombe RA Jr. Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro. Toxicol Appl Pharmacol. 1987;87:10-7.
57. Putignano P, Kaltsas GA, Satta MA, Grossman AB. The effects of anti-convulsant drugs on adrenal function. Horm Metab Res. 1998;30:389-97.
58. Rothmeier J, Froscher W. Connective tissue changes during long term anticonvulsive therapy. Fortschr Med. 1989;107:743-7.
59. Lefebvre EB, Haining RG, Labbe RF.Coarse facies, calvarial thickening and hyperphosphatasia associated with long-term anticonvulsant therapy. N Engl J Med. 1972;286:1301-2.
60. Falconer MA, Davidson S. Coarse features in epilepsy as a consequence of anticonvulsant therapy. Report of cases in two pairs of identical twins. Lancet. 1973;2:1112-4.
61. Herberg KP. Effects of diphenylhydantoin in 41 epileptics institutionalized since childhood. South Med J. 1977 ;70:19-24.
62. Livingston S, Peterson D, Boks LL. Hypertrichosis occurring in association with Dilantin therapy. J Pediatr 1955;47:351-2.
63. Trevisol-Bittencourt PC, da Silva VR, Molinari MA, Troiano AR. Phenytoin as the first option in female epileptic patients? Arq Neuropsiquiatr. 1999;57:784-6.
64. Greenwood R, Fenwick PB, Cunliffe WJ. Acne and anticonvulsants. Br Med J (Clin Res Ed). 1983;287:1669-70.
65. Ross S, Ormerod AD, Roberts C. Subacute cutaneous lupus erythematosus associated with phenytoin. Clin Exp Dermatol. 2002 ;27:474-6.
66. Dimachkie MM, Vriesendorp FJ, Heck KA. Phenytoin-induced dermatomyositis: case report and literature review. J Child Neurol. 1998;13:577-80.
67. Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol. 1993;16:19-29.
68. Gleichman H. Systemic lupus erythematous triggered by diphenylhydantoin. Arthritis Rheum. 1982;25:1387-8
69. Mangalvedhekar SS, Gogtay NJ, Manjula S, Kadam VS, Dalvi SS, Shah PU, Badakere SS, Pradhan VD, Kshirsagar NA. Phenytoin associated alopecia: drug induced lupus. J Assoc Physicians India. 2001;49:929-30.
70. Singsen BH, Fishman L, Hanson V. Antinuclear antibodies- and lupus-l ike syndromes in children receiving anticonvulsants. Pediatrics. 1976;57:529-34.
71. Zangemeister WH, Weisner B. A progressive systemic sclerosis like disease due to anticonvulsive therapy? Fortschr Neurol Psychiatr Grenzgeb. 1977;45:501-7.
72. Kashiwazaki S, Goto T, Okada J, Tadenuma T, Tazaki Y. Scleroderma developing during treatment of ictal stupor with diphenylhydantoin. Ryumachi. 1974;14:220-8.
73. Chakravarty K, al-Jafari MS. Phenytoin-induced pseudo-Sjögren syndrome. Br J Rheumatol. 1996;35:1033-4.
74. Kaur S, Goraya JS, Thami GP, Kanwar AJ. Pellagrous dermatitis induced by phenytoin. Pediatr Dermatol. 2002;19:93.
75. Hebestreit H, Pannenbecker J, Mingers AM, Bartels H. Pellagra in anticonvulsive therapy. Monatsschr Kinderheilkd. 1990;138:808-10.
76. Mock DM, Mock NI, Nelson RP, Lombard KA. Disturbances in biotin metabolism in children undergoing long-term anticonvulsant therapy. J Pediatr Gastroenterol Nutr. 1998;26:245-50.
77. Krause KH, Berlit P, Bonjour JP. Impaired biotin status in anticonvulsant therapy. Ann Neurol. 1982;12:485-6.
78. Krause KH, Berlit P, Bonjour JP. Reduction of biotin level as a possible factor in the mode of action of anticonvulsants. Arch Psychiatr Nervenkr. 1982;231:141-8.
79. Krause KH, Bonjour JP, Berlit P, Kochen W. Biotin status of epileptics. Ann N Y Acad Sci. 1985;447:297-313.
80. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ. Phenytoin-folic acid interaction. Ann Pharmacother. 1995;29:726-35.
81. Suzuki T, Koizumi J, Moroji T, Shiraishi H, Hori T, Baba A, Kawai N, Tada K. Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics. Biol Psychiatry. 1992;31:571-81.
82. Liu CS, Wu HM, Kao SH, Wei YH. Serum trace elements, glutathione, copper/zinc superoxide dismutase, and lipid peroxidation in epileptic patients with phenytoin or carbamazepine. Clin Neuropharmacol. 1998;21:62-4.
83. Ghose K, Taylor A. Hypercupraemia induced by antiepileptic drugs. Hum Toxicol. 1983;2:519-29.
84. Lewis-Jones MS, Evans S, Culshaw MA. Cutaneous manifestations of zinc deficiency during treatment with anticonvulsants. Br Med J (Clin Res Ed). 1985;290:603-4.
85. Kuzuya T, Hasegawa T, Shimizu K, Nabeshima T. Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. Int J Clin Pharmacol Ther Toxicol. 1993;31:61-5.
86.h Deb S, Cowie VA, Tsanaclis LM, Richens A.Calcium homeostasis in mentally handicapped epileptic patients. J Ment Defic Res. 1985;29 :403-10.
87. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002;58:1348-53.
88. Filardi S, Guerreiro CA, Magna LA, Marques Neto JF. Bone mineral density, vitamin D and anticonvulsant therapy. Arq Neuropsiquiatr. 2000;58:616-20.
89. Heldenberg D, Harel S, Holtzman M, Levtow O, Tamir I.The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology. 1983;33:510-13.
90. Rapp RP, Norton JA, Young B, Tibbs PA. Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery. 1983;13:272-5.
91. Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry. 2001;62 Suppl 14:22-6.
92. Pelekanos J, Camfield P, Camfield C, Gordon K. Allergic rash due to antiepileptic drugs: clinical features and management.Epilepsia. 1991;32:554-9.
93. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002 ;36:130-47.
94. Leong KP, Chng HH. Allergic reactions to phenytoin in a general hospital in Singapore. Asian Pac J Allergy Immunol. 1996 ;14:65-8
95. Sharma VK, Dhar S, Gill AN. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol. 1996;23:530-4.
96. Sharma VK, Vatve M, Sawhney IM, Kumar B. Clinical spectrum of drug rashes due to antiepileptics. J Assoc Physicians India. 1998;46:595-7.
97. Grunwald MH, Ben-Dor D, Livni E, Halevy S. Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs. Int J Dermatol. 1990;29:559-61.
98. Cohen AD, Reichental E, Halevy S. Phenytoin-induced severe cutaneous drug reactions: suspected interactions with corticosteroids and H2-blockers. Isr Med Assoc J. 1999;1:95-7.
99. Micali G, Linthicum K, Han N, West DP. Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy. 1999;19:223-7.
100. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention, and management.Drug Saf. 1999;21:489-501.
101. Kaur S, Sarkar R, Thami GP, Kanwar AJ.Anticonvulsant hypersensitivity syndrome. Pediatr Dermatol. 2002 ;19:142-5.
102. Nagai Y, Hattori T, Ishikawa O.A case of hypersensitivity syndrome due to phenytoin. J Dermatol. 2002;29:670-3.
103. Aihara M, Sugita Y, Takahashi S, Nagatani T, Arata S, Takeuchi K, Ikezawa Z. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol. 2001;144:1231-4.
104. Danno K, Kume M, Ohta M, Utani A, Ohno S, Kobashi Y. Erythroderma with generalized lymphadenopathy induced by phenytoin. J Dermatol. 1989;16:392-6.
105. Potter T, DiGregorio F, Stiff M, Hashimoto K. Dilantin hypersensitivity syndrome imitating staphylococcal toxic shock. Arch Dermatol. 1994;130:856-8.
106. Weedon AP. Diphenylhydantoin sensitivity. a syndrome resembling infectious mononucleosis with a morbilliform rash and cholestatic hepatitis. Aust N Z J Med. 1975;5:561-3.
107. Kleier RS, Breneman DL, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol. 1991;127:1361-4.
108. Stanley J, Fallon-Pellicci V. Phenytoin hypersensitivity reaction. Arch Dermatol. 1978;114:135-153.
109. Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity. Report of a case of hepatitis with jaundice, pyrexia, and exfoliative dermatitis. N Engl J Med. 1950;242:897-8.
110. Hamer HM, Morris HH. Successful treatment with gabapentin in the presence of hypersensitivity syndrome to phenytoin and carbamazepine: a report of three cases. Seizure. 1999 May;8(3):190-2.
111. Bessmertny O, Pham T.Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. Curr Allergy Asthma Rep. 2002;2:34-9.
112. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia. 1998;39 Suppl 7:S8-16
113. Yoo JH, Kang DS, Chun WH, Lee WJ, Lee AK. Anticonvulsant hypersensitivity syndrome with an epoxide hydrolase defect. Br J Dermatol. 1999;140:181-3
114. Gaffey CM, Chun B, Harvey JC, Manz HJ. Phenytoin-induced systemic granulomatous vasculitis. Arch Pathol Lab Med. 1986;110:131-5.
115. Schmutz J, Barbaud A, Trechot P. Purple hand syndrome and intravenous phenytoine. Ann Dermatol Venereol. 2000;127:548.
116. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia. 2001;42:1156-9.
117. O'Brien TJ, Cascino GD, So EL, Hanna DR.Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51:1034-9.
118. O'Brien TJ, Meara FM, Matthews H, Vajda FJ. Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology. 2001;57(8):1508-10.
119. Hunt SJ. Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin. Am J Dermatopathol. 1995;17:399-402.
120. Jamerson BD, Dukes GE, Brouwer KL, Donn KH, Messenheimer JA, Powell JR. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy. 1994;14:47-52.
121. Knapp LE, Kugler AR. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. J Child Neurol. 1998 Oct;13 Suppl 1:S15-8; discussion S30-2.
122. Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology. 1996;46(6 Suppl 1):S17-9.
123. Kanwar AJ, Jaswal R, Thami GP, Bedi GK. Acquired acromelanosis due to phenytoin. Dermatology. 1997;194:373-4.
124. Smith DA, Burgdorf WH. Universal cutaneous depigmentation following phenytoin-induced toxic epidermal necrolysis. J Am Acad Dermatol. 1984;10:106-9.
125. Ono T, Johno M, Kayashima K, Omori A. Anticonvulsant syndrome with multiple symptoms, including porphyria, IgA deficiency, and liver dysfunction. J Dermatol. 1990 Nov;17(11):684-9.
126. Yandel ML, Watters MR. Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Clin Neurol Neurosurg. 1995;97:261-3.
127. Herrick AL, McColl KE, Moore MR, Brodie MJ, Adamson AR, Goldberg A. Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity. Br J Clin Pharmacol. 1989;27:491-7.
128. Ruggian JC, Fishbane S, Demento FJ, Maesaka JK, Frei GL. Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. J Am Soc Nephrol. 1996;7:397-402.
129. Fuchs T, Seubert A, Seubert S, Ippen H. Anticonvulsant-induced unclassified porphyria. Int J Biochem. 1980;12:955-7.
130. Barzilay D, Orion E, Brenner S. Porphyria cutanea tarda triggered by a combination of three predisposing factors. Dermatology. 2001;203:195-7.
131. Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Leiferman KM, Peters MS. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol. 1994;30:187-92.
132. Sharma OP, Kalkat G. Drug induced clinical syndromes mimicking sarcoidosis. Sarcoidosis. 1991;8:3-5.
133. Rubinstein I, Baum GL, Hiss Y, Goldhammer Y. Does prolonged use of diphenylhydantoin predispose to pulmonary sarcoidosis? Eur Neurol. 1986;25:281-4.
134. Kattan KR. Thickening of the heel-pad associated with long-term Dilantin therapy. Am J Roentgenol Radium Ther Nucl Med. 197;124:52-6.
135. Weaver DK. Atypical lymphadenopathies of the head and neck. Crit Rev Clin Lab Sci. 1981;15:1-24.
136. Gams RA, Neal JA, Conrad FG. Hydantoin-induced pseudo-pseudolymphoma. Ann Intern Med. 1968;69:557-68.
137. Harris DW, Ostlere L, Buckley C, Whittaker S, Sweny P, Rustin MH. Phenytoin-induced pseudolymphoma. A report of a case and review of the literature. Br J Dermatol. 1992;127:403-6.
138. Greene DA. Localized cervical lymphadenopathy induced by diphenylhydantoin sodium. Arch Otolaryngol. 1975;101:446-8.
139. Schwinghammer TL, Howrie DL.Phenytoin-induced lymphadenopathy. Drug Intell Clin Pharm. 1983;17:460-2.
140. Braddock SW, Harrington D, Vose J. Generalized nodular cutaneous pseudolymphoma associated with phenytoin therapy. Use of T-cell receptor gene rearrangement in diagnosis and clinical review of cutaneous reactions to phenytoin. J Am Acad Dermatol. 1992;27:337-40.
141. Jeng YM, Tien HF, Su IJ. Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques. Epilepsia. 1996;37:104-7.
142. Cooke LE, Hardin TC, Hendrickson DJ. Phenytoin-induced pseudolymphoma with mycosis fungoides manifestations. Clin Pharm. 1988;7:153-7.
143. Rosenthal CJ, Noguera CA, Coppola A, Kapelner SN.Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer. 1982;49:2305-14.
144. Rijlaarsdam U, Scheffer E, Meijer CJ, Kruyswijk MR, Willemze R. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol. 1991;24:216-20.
145. Westhoven GS, Fretzin S, Lewis C. A woman with lung cancer and exfoliative dermatitis. Phenytoin-induced pseudo-mycosis fungoides syndrome (PMFS). Arch Dermatol. 1997;133:499, 502.
146. Wolf R, Kahane E, Sandbank M. Mycosis fungoides-like lesions associated with phenytoin therapy. Arch Dermatol. 1985;121:1181-2.
147. Adams JD. Localized cutaneous pseudolymphoma associated with phenytoin therapy: a case report. Australas J Dermatol. 1981;22:28-9.
148. Abbondazo SL, Irey NS, Frizzera G.Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns.Am J Surg Pathol. 1995;19:675-86.
149. Sorrell TC, Forbes IJ. Phenytoin sensitivity in a case of phenytoin-associated Hodgkin's disease. Aust N Z J Med. 1975;5:144-7.
150. Li FP, Willard DR, Goodman R, Vawter G. Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer. 1975;36:1359-62.
151. Charlton MH, Lusford D. Le sostanze di idantoina come possibili cause del linforma maligno. Minerva Med 1971:62:218.
152. Targan SR, Chassin MR, Guze LB. Dilantin-induced disseminated intravascular coagulation with purpura fulminans. A case report. Ann Intern Med. 1975;83:227-30.
153. Hanukoglu A, Fried D, Gotlieb A. Dyphenylhydantoin induced hypersensitivity reaction with an unusual purpuric skin lesion. Eur J Pediatr. 1980;134:177-9.
154. Zidar BL, Mendelow H, Winkelstein A, Shadduck AK. Diphenylhydantoin-induced serum sickness with fibrin-platelet thrombi in lymph node microvasculature. Am J Med. 1975;58:704-8.
155. Harrison RL, Alperin JB, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch Pathol Lab Med. 1987;111:719-22.
156. Howe AM, Lipson AH, Sheffield LJ, Haan EA, Halliday JL, Jenson F, David DJ, Webster WS. Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Am J Med Genet. 1995;58:238-44.
157. Hey E. Effect of maternal anticonvulsant treatment on neonatal blood coagulation. Arch Dis Child Fetal Neonatal Ed. 1999;81:F208-10.
158. Johnson RB, Goldsmith LA. Dilantin digital defects. J Am Acad Dermatol. 1981;5:191-6.
159. Nanda A, Kaur S, Bhakoo ON, Kapoor MM, Kanwar AJ. Fetal hydantoin syndrome: a case report. Pediatr Dermatol. 1989;6:130-3.
160. Verdeguer JM, Ramon D, Moragon M, Betlloch I, Jorda E, Planelles MV. Onychopathy in a patient with fetal hydantoin syndrome. Pediatr Dermatol. 1988;5:56-7.
161. Stankler L, Campbell AG. Neonatal acne vulgaris: a possible feature of the fetal hydantoin syndrome. Br J Dermatol. 1980;103:453-5.
162. Fris ML, Broeng-Nielsen B, Sindrup EH, Lund M, Fogh-Andersen P, Hauge M.Facial clefts among epileptic patients. Arch Neurol. 1981;38:227-9
163. Friis ML, Holm NV, Sindrup EH, Fogh-Andersen P, Hauge M.Facial clefts in sibs and children of epileptic patients. Neurology. 1986;36:346-50.
164. Owens JR, Jones JW, Harris F.Epidemiology of facial clefting. Arch Dis Child. 1985;60:521-4.
165. Friis ML. Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurol Scand. 1989;79:433-59.
166. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263-72.
© 2003 Dermatology Online Journal